Compounded Tirzepatide Dosage Guide & Chart
Understand prescribed amounts, vial concentrations and syringe scales without confusing a mathematical conversion with a treatment plan. The examples below are for adult-regimen context and must be matched to the actual prescription, product and device.
Understanding Tirzepatide and Its Advantages Over Semaglutide
Tirzepatide activates GIP and GLP-1 receptors; semaglutide activates GLP-1 receptors. The useful comparison is between studied regimens and populations, not an assumption that a larger milligram number means greater potency.
In the SURMOUNT-5 randomized trial, 751 adults with obesity without diabetes were randomized to receive maximum tolerated tirzepatide 10/15 mg or semaglutide 1.7/2.4 mg weekly. Mean weight changes at 72 weeks were −20.2% and −13.7%, respectively. Those results do not validate a particular compounded product or predict an individual's result.
Both groups commonly reported gastrointestinal events, mostly mild or moderate during escalation. The study does not justify saying tirzepatide universally causes more intense nausea. A product's benefit and tolerability still need individual assessment.
A compounded preparation requires its own identity, concentration, formulation and dispensing information. Sharing a named active ingredient with a brand does not establish identical finished-product performance.
Complete Tirzepatide Titration Schedule
There is no universally approved compounded-tirzepatide schedule. The following is adult branded-product context, not a prescription or a schedule selected by this website.
The Zepbound label starts at 2.5 mg weekly for four weeks, then 5 mg. Later increases are in 2.5 mg steps after at least four weeks at the current dose, considering response and tolerability. Weight-management maintenance doses are 5, 10 or 15 mg; the maximum is 15 mg. The 7.5 and 12.5 mg steps are not listed weight-management maintenance doses.
This does not mean everyone reaches the maximum by week 21. Do not shorten the interval to two or three weeks based on this chart. The Mounjaro label has its own indications and instructions, including a lower pediatric maximum; this page's examples are not pediatric guidance.
Tirzepatide Dosage Chart and Concentration Conversions
These retain the existing example amounts and concentrations while separating arithmetic from a calendar. The concentrations are examples, not a list of available or preferred pharmacy products. Only use your prescribed amount and the actual labeled concentration.
| Example amount (mg) | Volume at 5 mg/mL | Volume at 10 mg/mL | Volume at 20 mg/mL |
|---|---|---|---|
| 2.5 | 0.5 mL | 0.25 mL | 0.125 mL |
| 5 | 1 mL | 0.5 mL | 0.25 mL |
| 7.5 | 1.5 mL | 0.75 mL | 0.375 mL |
| 10 | 2 mL | 1 mL | 0.5 mL |
| 12.5 | 2.5 mL | 1.25 mL | 0.625 mL |
| 15 | 3 mL | 1.5 mL | 0.75 mL |
Some results exceed a 1 mL syringe. That is a reason to resolve the prescription/device mismatch with the pharmacy—not an instruction to split an injection, use several syringes, or change concentration yourself. Fitting in a barrel also does not establish injection suitability.
Calculating Injection Volume for Your Tirzepatide Concentration
Volume (mL) = prescribed amount (mg) ÷ concentration (mg/mL). On a confirmed U-100 scale only, multiply the volume by 100 to express it in U-100 units. These “units” describe the scale, not a biological unit of tirzepatide.
Example: 7.5 mg ÷ 5 mg/mL = 1.5 mL, corresponding to 150 U-100 units. This does not fit in a 1 mL/100-unit syringe; do not attempt to draw it into one. Verify the intended product, device and instructions with the pharmacy.
A concentration written in mg/mL is different from the total milligrams in a vial. For example, 10 mg in 2 mL would be 5 mg/mL, not 10 mg/mL. If the total amount and final volume are not clearly labeled, do not guess the denominator.
Choosing the Optimal Tirzepatide Concentration
There is no universal “best” concentration. The appropriate combination depends on the prescribed amount, actual measuring device and validated formulation. This guide does not establish that 5 mg/mL is the most common or that 20 mg/mL is the highest available.
For the same 2.5 mg example, 5, 10 and 20 mg/mL produce 0.5, 0.25 and 0.125 mL. Higher concentration reduces volume, but increases the amount represented by each scale division. Neither the smallest volume nor a full barrel is automatically preferable.
At 15 mg, those examples produce 3, 1.5 and 0.75 mL. The first two exceed 1 mL capacity; even 0.75 mL exceeds a 0.3 or 0.5 mL syringe. Have the pharmacy match the actual device and written instructions rather than treating “insulin syringe” as one size.
Converting from Insulin Syringes to Tirzepatide Dosing Units
Only a U-100 scale represents 100 units per mL. Confirm the scale and capacity on the supplied device; other insulin scales exist. The manufacturer's syringe guide lists different barrel sizes and half-unit scales on particular products—not on every syringe.
5 mg/mL examples: 2.5 mg = 50 U-100 units; 5 mg = 100 U-100 units; 7.5 mg = 150 U-100 units; 10 mg = 200 U-100 units; 12.5 mg = 250 U-100 units; 15 mg = 300 U-100 units. These are calculated scale equivalents, not confirmation that the volume fits or can be measured on your device.
10 mg/mL examples: 2.5 mg = 25 U-100 units; 5 mg = 50 U-100 units; 7.5 mg = 75 U-100 units; 10 mg = 100 U-100 units; 12.5 mg = 125 U-100 units; 15 mg = 150 U-100 units. These are calculated scale equivalents, not confirmation that the volume fits or can be measured on your device.
20 mg/mL examples: 2.5 mg = 12.5 U-100 units; 5 mg = 25 U-100 units; 7.5 mg = 37.5 U-100 units; 10 mg = 50 U-100 units; 12.5 mg = 62.5 U-100 units; 15 mg = 75 U-100 units. These are calculated scale equivalents, not confirmation that the volume fits or can be measured on your device.
Graduation spacing is not the same as accuracy. If a specific U-100 syringe has 0.5-unit graduations, one step is 0.005 mL. At 5, 10 and 20 mg/mL, that step represents 0.025, 0.05 and 0.1 mg respectively. It is not always 0.05 mg. A 0.01 mL graduation is twice that volume interval, not an improvement over a 0.005 mL interval.
Request a written conversion matching your vial and a demonstration using the supplied syringe. Do not obscure its scale with tape or estimate an unsupported fraction between marks.
Tirzepatide vs Semaglutide Dosing Comparison
The drugs are not interchangeable milligram for milligram. Ozempic and Wegovy are also different semaglutide products with different indications, maintenance regimens and presentations. The Wegovy injection instructions include the 1.7 mg escalation stage; 2.4 mg is not a universal maximum for every current semaglutide regimen.
Use the head-to-head trial above for that specific comparison, rather than juxtaposing “22% versus 15–18%” from unrelated trials. It does not prove that any two compounded preparations have the same outcomes as the tested products.
Compare total current costs at the prescribed regimen: medication, visits, supplies, shipping, membership charges, insurance and eligibility for manufacturer programs. A fixed percentage saving cannot be promised without like-for-like, dated quotes.
Proper Injection Technique for Tirzepatide
Obtain training for the exact product and device. Confirm the prescription in mg, the labeled concentration, the corresponding volume and the correct scale before drawing a dose. A correct calculation alone does not confirm that a treatment is appropriate.
Follow the product's preparation, injection-site and inspection directions. Expected appearance can depend on the formulation and added ingredients; a change can flag a problem, but clarity does not prove sterility. Do not substitute a generic warming time, needle angle or injection speed for device-specific instructions.
Use new sterile equipment as instructed, do not share patient-use medication or devices, and use appropriate sharps disposal. CDC injection-safety guidance provides the underlying handling principles; the pharmacy should explain how they apply to the supplied preparation.
Storage, Stability, and Vial Management
Follow the preparation's temperature limits and unopened expiry or beyond-use date. For compounded GLP-1 multidose vials, FDA currently recommends discarding within 28 days after first use, even when the compounder gives a longer interval. This is contamination-risk guidance, not proof of chemical stability for 28 days. A shorter supplied limit still applies; ask the dispensing pharmacy to reconcile conflicting instructions before further use.
Branded tirzepatide instructions prohibit freezing; this does not establish that every molecule is chemically destroyed by every freezing event. For a compounded vial that froze or experienced an uncertain excursion, set it aside and contact the pharmacy before further use. Do not invent “safe under one hour” or “discard after three hours” rules.
Keep the original labeled container and prevent a no-freeze product from contacting frozen packs during travel. Home-drawn syringes are not equivalent to manufacturer-filled or pharmacy-prepared syringes with documented storage instructions. See the storage and travel guide for those distinctions.
Dose Adjustments and Titration Modifications
Changes in dose or timing belong with the prescriber. Tolerating the current amount is not permission to accelerate a label's minimum escalation interval. The highest numerical dose is not automatically the right maintenance target.
Severe or persistent symptoms should prompt clinical advice, not a suggestion to remain at that dose for several more weeks. Seek urgent assessment for severe abdominal pain, inability to keep fluids down or signs of a serious allergic reaction. Product labels describe important risks and interactions beyond the scope of a conversion chart.
If response changes or weight loss plateaus, review the treatment with the clinician. This page cannot establish that switching medicines is rarely necessary or that escalation will restore an effect. After an interruption, obtain instructions rather than restarting an old higher dose from this table.
Comparison of Compounded vs Brand Tirzepatide
Mounjaro and Zepbound contain tirzepatide but have different labeled indications and product instructions. Mounjaro includes diabetes and a specified cardiovascular-risk indication; Zepbound includes adult weight management and obstructive sleep apnea. Zepbound weight management is not restricted to adults without diabetes.
Brand devices and vial presentations are not all “dial a dose” pens. Read the exact instructions supplied. Compounded preparations are not approved generic versions of these brands, and equal stated amounts do not establish equivalent absorption, quality, effects or adverse events.
Compounding has a clinical role, but whether a particular product can appropriately be prescribed and supplied depends on the patient, preparation and applicable requirements. Confirm the dispensing pharmacy, full ingredient list, labeled concentration, storage instructions and the basis for its quality claims. Do not infer approval of a finished product from a supplier's marketing language.
Cost and convenience remain useful comparison factors. Check current total quotes; this guide no longer treats a 60–75% saving or a particular monthly price as a verified universal fact.
Editorial update, September 8, 2026: corrected syringe precision, product/titration distinctions, unsupported equivalence and price claims, and storage instructions. Arithmetic examples were independently checked; they do not establish clinical suitability. Sourcing and corrections policy.
Related Guides & Resources
Frequently Asked Questions
There is no single schedule that validates every compounded product. For adult Zepbound, the label starts at 2.5 mg weekly for four weeks, then 5 mg; later 2.5 mg increases are considered only after at least four weeks at the current dose. Reaching 15 mg is not automatic. The prescriber selects the product-specific regimen; this page’s conversion examples do not select it.
Concentrations vary by preparation and pharmacy. This page uses 5, 10 and 20 mg/mL as arithmetic examples, not an exhaustive availability list or a recommendation. Use the concentration on your actual vial and the corresponding written instructions; do not carry an old syringe-unit amount across a concentration change.
Volume in mL equals the prescribed amount in mg divided by concentration in mg/mL. For example, 2.5 mg at 5, 10 or 20 mg/mL corresponds to 0.5, 0.25 or 0.125 mL. At 15 mg those example concentrations give 3, 1.5 or 0.75 mL. A calculated volume does not establish syringe capacity or injection suitability; have the pharmacy resolve a mismatch rather than splitting or altering the preparation yourself.
A shared ingredient name does not establish equivalent finished-product quality, absorption, efficacy or adverse effects. Compounded preparations are not approved generic versions of Mounjaro. Product formulation, concentration, device, dispensing instructions and total cost should be compared separately. Brand presentations are not all operated the same way.
Both contain tirzepatide, but their indications and product instructions differ. Mounjaro includes type 2 diabetes treatment and a cardiovascular-risk indication for specified adults with diabetes; Zepbound includes weight management and obstructive sleep apnea in specified adults. Zepbound is not limited to people without diabetes. Check the current label and presentation; do not assume identical concentrations, devices or maintenance instructions.
Syringe graduation spacing is not a guarantee of measurement accuracy. Only a U-100 scale has one unit equal to 0.01 mL. If a particular U-100 syringe has half-unit marks, each step is 0.005 mL: that contains 0.025 mg at 5 mg/mL, 0.05 mg at 10 mg/mL or 0.1 mg at 20 mg/mL. A 0.01 mL scale is coarser, not finer, than a 0.005 mL scale. Ask the pharmacy to match the actual device to the prescription.